drugset / Trial / NCT06623201

Blue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas

NCT06623201

Phase 1 Recruiting 20 enrolled Nathalie Zeitouni
NaSingle-groupOpen-labelTreatment

Summary

This research study is testing combination Blue-light photodynamic therapy and Sonidegib as a possible treatment for people with multiple basal cell carcinoma lesions. Basal cell carcinoma lesions are typically treated by freezing the lesion or surgically removing the lesion. These types of treatment can cause scarring. Photodynamic therapy uses light along with a drug applied to the skin to kill the cancer cells and cause them to break apart. The light used can cause the skin to feel warm, but does not cause scarring.

Timeline

Start
2024-10-07
Primary completion
2026-12-01
Completion
2026-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Aminolevulinic Acid Diagnostic / imaging agent Topical
Subject Sonidegib Small molecule 200 mg Oral

Indications